Huayi Pharmaceuticals has been ranked among the top 20 Chinese CDMO companies in 2020

On September 10th, the 2020 Conference on High Quality Development of Healthcare Industry & the Fifth Summit for China Pharmaceutical R&D and Innovation (PDI Conference) opened in Chongqing. With the theme of “Formulation Innovation, Leading the Future”, this conference launched in-depth exchanges from various aspects such as “Innovation and Development of Pharmaceutical Preparations” and “Seminar on Key Technologies of Preparation Development”, responding to hot issues, empowering industry development and helping the pharmaceutical industry stepping towards internationalization, which can be described as an annual high-end summit of industry influence.

On the first day of the conference, the “2020 China Drug R&D Strength Ranking List” was solemnly released. The selection committee comprehensively considered many criteria such as corporate management capabilities, clinical research strength, brand influence, turnover, industry reputation, etc., and selected six major industry lists including drug R&D strength, CRO companies and CDMO companies. Huayi Pharmaceuticals won the honorary title of “2020 China Top 20 CDMO Enterprises”.

This award is not only an honor but also represents the industry’s high recognition on Huayi’s achievements. In the future, we will continue to make new contributions to the medical and health industry with professional technology, dedicated attitude and credible quality!